Innovotech Inc. (TSX Venture Exchange: IOT; OTCQB: IOTCF) reported financial results for the first quarter ended March 31, 2026, revealing a significant decline in revenue and a shift to net loss as the company grapples with client concentration issues. Revenue for the quarter was $648,140, a 44% decrease from the same period in 2025, driven almost entirely by changes in a large project for a major customer that had been expected to continue through 2026.
Gross profit fell to $202,231, with a gross margin of 31.2%, down from 53.6% in the prior year. The margin compression was attributed to underutilized capacity as Innovotech maintained staffing and operational readiness in anticipation of the planned customer work. The company recorded a net and comprehensive loss of $401,295, compared to net income of $63,523 in Q1 2025. Operating expenses increased year over year, reflecting the integration of Keystone Labs and Innovotech Labs, relocation of the former Keystone Labs operations, and investments in a stronger sales organization.
Despite the quarterly setback, Innovotech continues to advance its strategic transformation. The company strengthened its leadership and commercial teams and completed its OTCQB listing in the U.S. Innovotech maintains a strong liquidity position and a meaningful equity base, providing flexibility to manage near-term volatility while executing its longer-term strategy. CEO Craig Milne stated, “Management remains committed to investing in a more diversified, resilient, and scalable platform. The Company is continuing to execute its transformation strategy with a focus on the operational and commercial initiatives required to support long-term growth and reduce revenue concentration risk.”
The company, which operates ISO-certified and GMP-accredited laboratories, specializes in contract research, analytical, and microbial testing within regulated healthcare markets. It is a recognized leader in biofilm science and antimicrobial testing, providing advanced laboratory services that support medical device, pharmaceutical, and industrial product development. Innovotech’s proprietary MBEC Assay® platform is widely used for high-throughput antimicrobial and antibiotic testing. The company serves clients across multiple sectors and geographies, delivering data aligned with regulatory expectations such as those of the U.S. Food and Drug Administration and Health Canada.
The Q1 results underscore the risks of client concentration, which Innovotech is actively addressing by expanding its service offerings and commercial capabilities to generate more consistent recurring revenue. The company’s unaudited consolidated financial statements and Management’s Discussion and Analysis have been filed on SEDAR+ and the OTCIQ. More information about Innovotech is available at https://www.innovotech.ca.
